117
Participants
Start Date
October 31, 2016
Primary Completion Date
October 31, 2017
Study Completion Date
November 30, 2017
NATESTO Testosterone Nasal Gel
"Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 \[Day 90\] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone."
Prostate Cancer Centre - Research, Calgary
Silverado Research Inc., Victoria
LMC Barrie, Barrie
G. Kenneth Jansz Medicine Professional Corporation, Burlington
Lawson Research Institute / St Joseph's Health Care London, London
The Fe/Male Health Centre, Oakville
Toronto Urology Clinical Study Group, Toronto
Rabih Nour Clinic Windsor, Windsor
Ultra-Med Inc., Pointe-Claire
Clinique D'Andropause de Quebec, Québec
Dr. Carlos Marois Urologue, Verdun
Lead Sponsor
Acerus Pharmaceuticals Corporation
INDUSTRY